Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Zacks Investment Research, Inc.
CHICAGO, Jan. 20, 2014 /PRNewswire/ -- Zacks Equity Research highlights Lazard Ltd. (NYSE:LAZ-Free Report) as the Bull of the Day and Full House Resorts (Nasdaq:FLL-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis onLife Technologies Corp. (Nasdaq:LIFE-Free Report), Thermo Fisher Scientific, Inc. (NYSE:TMO-Free Report) and General Electric Co. (NYSE:GE-Free Report).
Here is a synopsis of all five stocks:
Investment Management and Financial Advisory industry is expected to report strong results for Q4 2013. Now may be a good time to consider a Zacks Rank # 1 (Strong Buy) from this top rated industry.
Lazard Ltd. (NYSE:LAZ-Free Report) is a leading global financial advisory and asset management firm with more than $175 billion in AUM. It operates from 40 cities across 26 countries in North America, Europe, Asia, Australia, Central and South America.
The firm provides advice on mergers and acquisitions (M&A), strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services.
Lazard reported it Q3 results on October 24, 2013. Adjusted earnings for the quarter came in at $0.46 per share, handily beating the Zacks Consensus Estimate of $0.35 per share and significantly up from $0.26 per share earned in the same quarter last year.
Excellent results were driven by strong top-line performance, thanks mainly to increase in financial advisory as well as asset management revenues.
Full House Resorts (Nasdaq:FLL-Free Report) is a casino gaming company, incorporated in 1987. The company owns local casinos as well as manages casinos on behalf of Native American tribes and commercial clients. Currently FLL owns and/or manages five casinos in four states.
Declining estimates sent FLL back to a Zacks Rank # 5 (Strong Sell) earlier this month.
On November 9, 2012, FLL reported its third quarter results. Adjusted operating net income for the quarter were $0.5 million or $0.02 per share, compared to net income of $2.1 million or $0.11 per share in the prior-year period.
Earnings were substantially short of the Zacks Consensus Estimate of $0.06 per share. This was the second consecutive quarter of negative earnings surprise for FLL.
According to the management, increased competition and continuing slow economy resulted in a challenging environment.
Following disappointing results, analysts have cut their estimates for GGS. Zacks Consensus Estimates for the current year and the next year are currently $0.02 per share and $0.07 per share, down from $0.04 per share and $0.11 per share respectively, 60 days ago.
Thermo Fisher-Life Deal OK'd in China
Subsequent to the European Commission's (EC) conditional approval of the impending $13.6 billion (or $76 per share) acquisition of Life Technologies Corp. (Nasdaq:LIFE-Free Report), Thermo Fisher Scientific, Inc. (NYSE:TMO-Free Report) recently received the Chinese regulatory nod for the same. As per several recent reports including one from Reuters, China's Ministry of Commerce lately approved Thermo Fisher's acquisition of Life Technologies subject to certain conditions.
These conditions include divestment of TMO's cell culture and gene modulation business, price cuts on two of the company's products (SSP kits and SDS-PAGE protein standards) that are sold in China, and sale of Thermo Fisher's 51% stake in China's Lanzhou National Hyclone Bio-engineering Co Ltd.
We note that, some of these conditions are similar to those demanded by the EC which conditionally cleared the deal in November. Last week, to fulfill the conditions put forward by the EC, Thermo Fisher inked a deal to divest 3 of its business divisions to GE Healthcare, a unit of General Electric Co. (NYSE:GE-Free Report). Per the deal, GE Healthcare will buy Thermo Fisher's gene modulation, cell culture and magnetic beads businesses for about $1.06 billion.
In addition, Thermo Fisher needs certain other additional regulatory go-aheads to close the LIFE takeover. This includes a clearance from the U.S. Federal Trade Commission (FTC). The company is currently working on completing this transaction by early 2014.
In Aug 2013, more than 98% of the shareholders of Life Technologies (representing more than 72% of the company's outstanding shares) had voted in favor of this merger agreement. Prior to that, on Apr 15, Thermo Fisher had disclosed its plans to acquire LIFE for roughly $13.6 billion plus the assumption of the latter's net debt ($2.2 billion as of year-end 2012).
The total purchase price includes cash and debt of $9.5–$10.0 billion and as much as $4.0 billion in equity. EC's support in this regard is considered to be a major positive and a big milestone for the deal to finally go through.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
©2012 PR Newswire. All Rights Reserved.
WLBT 3 - Fox 40
715 South Jefferson Street